PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.

NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

ADTN reports lackluster results in the third-quarter of 2024 due to soft demand trends in the Network Solutions business.

RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS...

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.